Manik Amin is an Oncology physician affiliated with Dartmouth–Hitchcock Medical Center. OpenAlex indexes 93 publications with 1,053 citations (h-index 19); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5841 S Maryland Ave
Chicago, IL 606371443
Telephone
773-702-1000Provider last certified this registry record 3 Jun 2026.
Clinical trials
- Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
Sponsor: University of Chicago
- Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- Ipsen Biopharmaceuticals, IncProgram year20242 payments
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Phenothiazine100%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Association of DPYD rs4294451, plasma uracil concentration, and sex with 5-fluorouracil exposure in patients with gastrointestinal cancer
Cancer Chemotherapy and Pharmacology
2025 - Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline
Journal of Clinical Oncology
2024 - Association between activating <i>GNAS</i> mutations and outcomes with chemotherapy in metastatic appendiceal adenocarcinoma.
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Meehan, MD
Dartmouth–Hitchcock Medical Center
Thamolwan Surakiatchanukul, MD
Dartmouth–Hitchcock Medical Center
Payam Moein, MD
Dartmouth–Hitchcock Medical Center
Linda Vahdat, MD
Dartmouth–Hitchcock Medical Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”